BioSpace News Archive

Research Provides Proof That Cellular RPM™ Is Easy To Use And Can Improve Outcomes

Three recent patient research reports show that cellular remote patient monitoring™(RPM) programs are an effective way for patients to become more involved with their care between visits to their healthcare provider.

December 14, 2023
·
3 min read
Genetown

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.

December 14, 2023
·
1 min read
Pharm Country

B. Braun Launches the CARESITE Micro™ Luer Access Device and Extension Sets

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new CARESITE Micro™ Luer Access Device, designed to reduce exposure to harmful chemicals and decrease infection risk, making IV access safer for patients and healthcare providers.

December 14, 2023
·
2 min read
Pharm Country

CSL’s Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for garadacimab (CSL312) as a once-monthly prophylactic treatment for hereditary angioedema (HAE).

December 14, 2023
·
4 min read
Genetown

Syndax Announces Proposed $150 Million Public Offering of Common Stock

Syndax Pharmaceuticals, Inc. announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering.

December 14, 2023
·
4 min read
Biotech Beach

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Aadi Bioscience, Inc. (NASDAQ: AADI) today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.

December 14, 2023
·
8 min read
Business

Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”) today reported its financial results for the fiscal year ended August 31, 2023.

December 14, 2023
·
17 min read
Genetown

Syndax Announces Pricing of $200 Million Public Offering of Common Stock - December 15, 2023

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 10,810,810 shares of its common stock.

December 14, 2023
·
4 min read
Addex Creates Treasury Shares - December 14, 2023

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that 15,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.

December 14, 2023
·
3 min read
Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay

Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies.

December 14, 2023
·
3 min read